[Pulmonary embolism and direct oral anticoagulants]

Area of Science:

• Medicine
• Cardiology
• Hematology

Background:

• The 2014 European guideline for venous thromboembolism (VTE) diagnosis and therapy has been released.
• Pulmonary embolism (PE) risk stratification now includes intermediate-risk categories, influencing diagnostic and therapeutic decisions.

Purpose of the Study:

• To provide a rapid orientation on the updated European guidelines for VTE diagnostics and therapy.
• To highlight the role of direct oral anticoagulants (DOACs) in managing acute and long-term VTE.

Main Methods:

• Review of the 2014 European Society of Cardiology (ESC) guidelines for VTE.
• Comparison of traditional VTE therapy (heparinoids followed by vitamin K antagonists) with newer direct oral anticoagulants (DOACs).

Main Results:

• The updated guideline stratifies PE into high, low, and intermediate risk categories.
• Direct oral anticoagulants (DOACs) offer rapid onset of action, similar to heparinoids.
• DOACs allow for long-term oral anticoagulation without the need for frequent coagulation monitoring, unlike vitamin K antagonists.

Conclusions:

• Risk stratification is crucial for guiding VTE diagnosis and treatment.
• DOACs represent a significant advancement in VTE therapy, offering convenience and efficacy.
• While generally easy to dose, some patients may require dose adjustments for DOACs.